| Name | Title | Contact Details |
|---|---|---|
Robert Budenholzer |
Vice President and General Counsel, North America | Profile |
Ed Porter |
Vice President of Compliance | Profile |
Autohuset Vestergaard A/S, Personvogne er blandt landets største bilvirksomheder. Vi har autoriseret salg af 11 bilmærker - Volvo, Polestar, Renault, KIA, Ford, Mazda, Dacia, Nissan, Maxus, JAC og BYD. Vi er repræsenteret med 12 filialer - Autohuset Vestergaard beskæftiger cirka 450 medarbejdere og sælger årligt mere end 15.000 nye og brugte biler. Vi er specialister inden for person- og varebiler til private og erhvervsdrivende. Autohuset Vestergaard skræddersyer en løsning, der matcher netop dit behov. Hvad end du ønsker at lease eller eje, så har vi løsningen til dig. Alle vores værksteder er ISO-certificerede og bemandet med top professionelle medarbejdere, der sikrer optimal pleje af din bil, uanset om det gælder service, reparation eller skadearbejde. Hos Autohuset Vestergaard er det vores målsætning, at skabe langsigtede relationer med vores kunder. I vores daglige arbejder bestræber vi os altid på at yde den indsats, der skal til, for at vi opnår yderst tilfredse kunder.
MACC Investment Group will endeavor to re-energize portfolio brands by providing consistent supportive leadership. We hold our internal support teams accountable to the task of delivering on a mission that supports improving guest transactions concurrent with growing market share. We will develop and coach behaviors that drive performance while holding our corporate team accountable in a business environment that rewards and celebrates improved diligence and fiscal responsibility.
As of December 31st, 2023, the XFL has officially merged with the USFL to create the United Football League (UFL). Our spring football legacy continues in 2024 under a new name, with the same goal: to make the spring football opportunity as strong as it can be. See you at a game! theUFL.com/tickets
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.